Get the Stockscreener App
12.31
1.56%
-0.20
Day One Biopharmaceuticals Inc stock is traded at $12.31, with a volume of 386.96K.
It is down -1.56% in the last 24 hours and down -0.68% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
See More
Previous Close:
$12.51
Open:
$12.45
24h Volume:
386.96K
Relative Volume:
0.37
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
$-167.48M
P/E Ratio:
-6.3128
EPS:
-1.95
Net Cash Flow:
$-197.47M
1W Performance:
-0.44%
1M Performance:
-0.68%
6M Performance:
-3.18%
1Y Performance:
-19.93%
1-Day Range:
$12.21
$12.61
1-Week Range:
$11.93
$12.65
52-Week Range:
$11.13
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Compare DAWN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.32 | 1.26B | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.63 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.52 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.75 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Day One Biopharmaceuticals Inc (DAWN) Shares Up Despite Recent Market Volatility - The News Heater
The Top 12 Companies Hiring in Biopharma Now - BioSpace
A closer look at Day One Biopharmaceuticals Inc (DAWN)’s stock price trends - US Post News
Balance Sheet Insights: Day One Biopharmaceuticals Inc (DAWN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Financial Metrics Unveiled: Ginkgo Bioworks Holdings Inc (DNA)’s Key Ratios in the Spotlight - The Dwinnex
How To Trade (DAWN) - Stock Traders Daily
You might want to take a look at Day One Biopharmaceuticals Inc (DAWN) now - SETE News
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer - Seeking Alpha
SG Americas Securities LLC Buys Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of Directors - Yahoo Finance
SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Reviewing Day One Biopharmaceuticals (NASDAQ:DAWN) and Nature’s Sunshine Products (NASDAQ:NATR) - Defense World
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
(DAWN) Trading Report - Stock Traders Daily
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? - Yahoo Finance
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5) - Seeking Alpha
Where are the Opportunities in (DAWN) - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha
(DAWN) On The My Stocks Page - Stock Traders Daily
High Growth Tech Stocks to Watch in December 2024 - Simply Wall St
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
State Street Corp Sells 3,003 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan
Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Children's Brain Tumor Network Partners with Day One Biopharmaceuticals to Drive New Therapies for Pediatric Brain Tumors - Marketscreener.com
Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com
Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Day One Biopharmaceuticals Inc Stock (DAWN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Nov 18 '24 |
Sale |
13.21 |
10,554 |
139,420 |
108,377 |
| Blackman Samuel C. | HEAD OF R&D |
Nov 18 '24 |
Sale |
13.21 |
2,206 |
29,142 |
1,064,015 |
| Dubow Adam | GENERAL COUNSEL |
Nov 18 '24 |
Sale |
13.21 |
3,165 |
41,810 |
32,162 |
| York Charles N II | COO, CFO AND SECRETARY |
Nov 18 '24 |
Sale |
13.21 |
2,602 |
34,373 |
240,133 |
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):